Table 5 -.
Comparison of clinical characteristics according to absolute lymphocyte count on post-bone marrow transplantation (BMT) day 60 (ALC60)
| ALC60 ≤300/μL | ALC60 >300/μL | ||
|---|---|---|---|
| Measure | (N=134) | (N=353) | p-value |
| Age (years), median (range) | 46 (18–71) | 47 (18–71) | 0.75 |
| Diagnosis, n (%) | |||
| AML/MDS | 105 (78) | 292 (83) | 0.27 |
| ALL | 29 (22) | 61 (17) | |
| Donor type, n (%) | |||
| Matched unrelated | 97 (72) | 230 (65) | 0.11 |
| Mismatch unrelated | 13 (10) | 45 (13) | |
| Haploidentical | 17 (13) | 37 (10) | |
| Matched related | 7 (5) | 41 (12) | |
| Matched donor, n (%) | |||
| Yes | 104 (78) | 271 (77) | 0.84 |
| No | 30 (22) | 82 (23) | |
| Related donor, n (%) | |||
| Yes | 24 (18) | 78 (22) | 0.31 |
| No | 110 (82) | 275 (78) | |
| CR at BMT, n (%) | |||
| Yes | 63 (47) | 185 (52) | 0.29 |
| No | 71 (53) | 168 (48) | |
| TBI-based conditioning, n (%) | |||
| Yes | 26 (19) | 39 (11) | 0.0155 |
| No | 108 (81) | 314 (89) | |
| Busulfan-based conditioning, n (%) | |||
| Yes | 63 (47) | 218 (62) | 0.0033 |
| No | 71 (53) | 135 (38) | |
| Conditioning intensity, n (%) | |||
| Myeloablative | 97 (72) | 283 (80) | 0.06 |
| Reduced-intensity | 37 (28) | 70 (20) | |
| ATG or alemtuzumab, n (%) | |||
| Yes | 96 (72) | 254 (72) | 0.95 |
| No | 38 (28) | 99 (28) | |
| Post-BMT cyclophosphamide, n (%) | |||
| Yes | 12 (9) | 31 (9) | 0.95 |
| No | 122 (91) | 322 (91) | |
| Graft total nucleated cell count | |||
| continuous, median(range) | 2.42 (0.03 – 6.26) | 2.67 (0.15 – 12.37) | 0.13 |
| ≤ 2.59*, n (%) | 73 (54) | 171 (48) | 0.23 |
| > 2.59, n (%) | 61 (46) | 182 (52) | |
| Graft CD34+ cell count | |||
| continuous, median(range) | 2.99 (0 – 9.57) | 3.12 (0 – 12.67) | 0.24 |
| ≤ 3.03*, n (%) | 73 (54) | 171 (48) | 0.23 |
| > 3.03, n (%) | 61 (46) | 182 (52) | |
| Graft CD3+ cell count | |||
| continuous, median(range) | 18.79 (0 – 69.02) | 21.16 (0 – 83.13) | 0.20 |
| ≤ 20.43*, n (%) | 75 (56) | 166 (48) | 0.10 |
| > 20.43, n (%) | 59 (44) | 182 (52) | |
ALL: Acute lymphoid leukemia, AML: Acute myeloid leukemia, ATG: Anti-thymocyte globulin, CR: Complete remission, MDS: Myelodysplastic syndrome, TBI: Total body irradiation